Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia-Reference-Cited by-同舟云学术

Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia

Published:2015-08-01 Issue:8 Volume:72 Page:822
ISSN:2168-622X
Container-title:JAMA Psychiatry
language:en
Short-container-title:JAMA Psychiatry

Author:

Subotnik Kenneth L.¹,Casaus Laurie R.¹,Ventura Joseph¹,Luo John S.¹,Hellemann Gerhard S.¹,Gretchen-Doorly Denise¹,Marder Stephen²,Nuechterlein Keith H.³

Affiliation:

1. Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA (University of California, Los Angeles)

2. Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA (University of California, Los Angeles)2Department of Psychiatry, Veterans Affairs Greater Los Angeles Health

3. Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA (University of California, Los Angeles)3Department of Psychology, UCLA

Publisher

American Medical Association (AMA)

Subject

Psychiatry and Mental health

Cited by 213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early intervention in psychosis in low- and middle-income countries: Applying the same principles as the developed countries;Asian Journal of Psychiatry;2024-09

2. An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder;Expert Review of Neurotherapeutics;2024-07-23

3. A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial;CNS Drugs;2024-07-02

4. Second Opinions for Diagnoses of Psychotic Disorders: Delivering Stage-Specific Recommendations;Psychiatric Services;2024-06-28

5. In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan;JAMA Network Open;2024-06-17